vs
CorMedix Inc.（CRMD）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是CorMedix Inc.的1.2倍（$151.1M vs $128.6M），CorMedix Inc.自由现金流更多（$92.7M vs $12.3M）
CorMedix Inc.是一家处于商业阶段的生物制药企业，专注于开发及商业化用于预防和治疗感染性、炎症性及心肾疾病的创新治疗产品，核心管线针对导管相关血流感染，主要服务北美、欧洲的重症监护及长期透析患者群体。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
CRMD vs RGR — 直观对比
营收规模更大
RGR
是对方的1.2倍
$128.6M
自由现金流更多
CRMD
多$80.4M
$12.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $128.6M | $151.1M |
| 净利润 | — | — |
| 毛利率 | 83.4% | 17.8% |
| 营业利润率 | 46.0% | 2.3% |
| 净利率 | — | — |
| 营收同比 | — | 3.6% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.20 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRMDRGR
| Q4 25 | $128.6M | $151.1M | ||
| Q3 25 | $104.3M | $126.8M | ||
| Q2 25 | $39.7M | $132.5M | ||
| Q1 25 | $39.1M | $135.7M | ||
| Q4 24 | — | $145.8M | ||
| Q3 24 | — | $122.3M | ||
| Q2 24 | — | $130.8M | ||
| Q1 24 | — | $136.8M |
净利润CRMDRGR
| Q4 25 | — | — | ||
| Q3 25 | $108.6M | $1.6M | ||
| Q2 25 | $19.8M | $-17.2M | ||
| Q1 25 | $20.6M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $4.7M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | — | $7.1M |
毛利率CRMDRGR
| Q4 25 | 83.4% | 17.8% | ||
| Q3 25 | 89.3% | 15.1% | ||
| Q2 25 | 95.3% | 3.9% | ||
| Q1 25 | 95.9% | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
营业利润率CRMDRGR
| Q4 25 | 46.0% | 2.3% | ||
| Q3 25 | 49.2% | -2.7% | ||
| Q2 25 | 49.2% | -15.6% | ||
| Q1 25 | 51.5% | 6.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | — | 5.5% |
净利率CRMDRGR
| Q4 25 | — | — | ||
| Q3 25 | 104.1% | 1.2% | ||
| Q2 25 | 49.9% | -13.0% | ||
| Q1 25 | 52.8% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 5.2% |
每股收益（稀释后）CRMDRGR
| Q4 25 | $0.20 | $0.22 | ||
| Q3 25 | $1.26 | $0.10 | ||
| Q2 25 | $0.28 | $-1.05 | ||
| Q1 25 | $0.30 | $0.46 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | — | $0.47 | ||
| Q1 24 | — | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $148.5M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $405.3M | $283.8M |
| 总资产 | $826.1M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRMDRGR
| Q4 25 | $148.5M | $92.5M | ||
| Q3 25 | $55.7M | $80.8M | ||
| Q2 25 | $190.7M | $101.4M | ||
| Q1 25 | $77.5M | $108.3M | ||
| Q4 24 | — | $105.5M | ||
| Q3 24 | — | $96.0M | ||
| Q2 24 | — | $105.6M | ||
| Q1 24 | — | $115.3M |
股东权益CRMDRGR
| Q4 25 | $405.3M | $283.8M | ||
| Q3 25 | $374.1M | $279.6M | ||
| Q2 25 | $220.6M | $289.3M | ||
| Q1 25 | $114.9M | $321.5M | ||
| Q4 24 | — | $319.6M | ||
| Q3 24 | — | $314.9M | ||
| Q2 24 | — | $321.5M | ||
| Q1 24 | — | $332.0M |
总资产CRMDRGR
| Q4 25 | $826.1M | $342.0M | ||
| Q3 25 | $750.9M | $342.3M | ||
| Q2 25 | $252.6M | $349.5M | ||
| Q1 25 | $149.6M | $379.0M | ||
| Q4 24 | — | $384.0M | ||
| Q3 24 | — | $373.5M | ||
| Q2 24 | — | $376.7M | ||
| Q1 24 | — | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.5M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $92.7M | $12.3M |
| 自由现金流率自由现金流/营收 | 72.1% | 8.2% |
| 资本支出强度资本支出/营收 | 1.3% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $172.8M | $38.5M |
8季度趋势，按日历期对齐
经营现金流CRMDRGR
| Q4 25 | $94.5M | $15.5M | ||
| Q3 25 | $30.9M | $12.9M | ||
| Q2 25 | $30.0M | $14.7M | ||
| Q1 25 | $19.7M | $11.1M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | — | $7.3M |
自由现金流CRMDRGR
| Q4 25 | $92.7M | $12.3M | ||
| Q3 25 | $30.4M | $7.0M | ||
| Q2 25 | $30.0M | $9.1M | ||
| Q1 25 | $19.7M | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
自由现金流率CRMDRGR
| Q4 25 | 72.1% | 8.2% | ||
| Q3 25 | 29.1% | 5.5% | ||
| Q2 25 | 75.4% | 6.9% | ||
| Q1 25 | 50.5% | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
资本支出强度CRMDRGR
| Q4 25 | 1.3% | 2.1% | ||
| Q3 25 | 0.5% | 4.6% | ||
| Q2 25 | 0.1% | 4.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 1.3% |
现金转化率CRMDRGR
| Q4 25 | — | — | ||
| Q3 25 | 0.28× | 8.15× | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.96× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
